Opening soonPhase 2Ages 18 Years and up
Bacterial Decolonization Plus Intraoperative Angiography for Soft Tissue Sarcomas Receiving Preoperative Radiotherapy (CONCERTO)
Sponsor: Adam Olson · NCT06712433 on ClinicalTrials.gov ↗
Conditions studied
Sarcoma,Soft Tissue
What it tests
- 2% intranasal mupirocin ointmentdrug
- 4% chlorhexidine gluconate body cleanserdrug
Where it's running1 site
UPMC Hillman Cancer Centers
Pittsburgh, Pennsylvania 15232
- Samantha Demko, RN(contact)412-623-1400[email protected]
- Brieanna Marino, MS(contact)412-647-8258[email protected]
- Adam Olson, MD(principal investigator)
See the official eligibility language
Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.
Inclusion Criteria: 1. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2 2. Newly diagnosed soft tissue sarcoma arising from the lower extremity (defined as the tumor center arising at the level of the iliac crest or below) 3. Eligible for wide local excision 4. Eligible for external beam radiation therapy 5. Negative serum pregnancy test for women of childbearing potential \< 28 days prior to RT. 6. Informed consent signed and dated to participate in the study. 7. Willingness and ability to comply Exclusion Criteria: 1. Allergy to mupirocin and/or chlorhexidine 2. Active dermatologic condition in RT field 3. Tumor size \> 32cm 4. Prior RT overlapping with fields 5. Concurrent/prior invasive malignancy that could potentially interfere with proposed treatment. Individual cases can be discussed with PI prior to registration
Updated 2026-02-09 on ClinicalTrials.gov. Always confirm current details with the study team or your oncologist.